{"id":"glp-1-analogs","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1240772","moleculeType":"Protein","molecularWeight":"3169.55"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"GLP-1 analogs bind to and activate the GLP-1 receptor, which increases insulin secretion and decreases glucagon secretion. This leads to improved glycemic control and weight loss in patients with type 2 diabetes.","oneSentence":"GLP-1 analogs mimic the action of the hormone glucagon-like peptide-1 to regulate blood sugar levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:38:33.550Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Weight management"}]},"trialDetails":[{"nctId":"NCT06278285","phase":"NA","title":"Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2024-03-06","conditions":"Obesity","enrollment":40},{"nctId":"NCT07483801","phase":"PHASE4","title":"DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies","status":"NOT_YET_RECRUITING","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2026-03","conditions":"Cardiovascular Diseases","enrollment":112},{"nctId":"NCT07478198","phase":"NA","title":"Study on the Efficacy and Safety of PLLA Injections for Improving Facial Laxity Following GLP-1 Analog Therapy","status":"ENROLLING_BY_INVITATION","sponsor":"Shanghai Punan Hospital of Pudong New District","startDate":"2025-07-03","conditions":"Facial Skin Laxity","enrollment":22},{"nctId":"NCT07457424","phase":"","title":"Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College Dublin","startDate":"2022-02-17","conditions":"Metabolic Disease, Obesity & Overweight","enrollment":140},{"nctId":"NCT06512584","phase":"PHASE3","title":"Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition","status":"RECRUITING","sponsor":"Chongqing Peg-Bio Biopharm Co., Ltd.","startDate":"2024-09-03","conditions":"Short Bowel Syndrome","enrollment":72},{"nctId":"NCT06027567","phase":"PHASE4","title":"The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure","status":"COMPLETED","sponsor":"Rigmor Højland Jensen","startDate":"2022-09-02","conditions":"Idiopathic Intracranial Hypertension, Intracranial Pressure, Obesity","enrollment":38},{"nctId":"NCT07428746","phase":"PHASE3","title":"Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Emory University","startDate":"2026-04","conditions":"Diabetes Mellitus, Type 2","enrollment":20},{"nctId":"NCT05356104","phase":"PHASE2","title":"GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2022-05-25","conditions":"Cerebral Small Vessel Disease","enrollment":110},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT06897202","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Metsera, a wholly owned subsidiary of Pfizer","startDate":"2025-03-14","conditions":"Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)","enrollment":133},{"nctId":"NCT06712836","phase":"PHASE2","title":"A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight","status":"ACTIVE_NOT_RECRUITING","sponsor":"Metsera, a wholly owned subsidiary of Pfizer","startDate":"2024-10-24","conditions":"Obesity, Overweight or Obesity","enrollment":225},{"nctId":"NCT07401992","phase":"PHASE4","title":"Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2026-01-15","conditions":"Psoriasis (PsO), Obesity & Overweight, Diabetes Mellitus - Type 2","enrollment":62},{"nctId":"NCT07400783","phase":"NA","title":"TED_ORG: Study on Short Bowel Syndrome","status":"RECRUITING","sponsor":"Meyer Children's Hospital IRCCS","startDate":"2024-10-30","conditions":"Short Bowel Syndrome (SBS)","enrollment":50},{"nctId":"NCT04779697","phase":"PHASE1","title":"GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-02-01","conditions":"Obesity","enrollment":96},{"nctId":"NCT07398222","phase":"","title":"Gastric Content in Fasting Volunteers and in Tirzepatide Users: an Observational and Cross-sectional Study","status":"RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2026-01-26","conditions":"Full Stomach Status","enrollment":30},{"nctId":"NCT02674893","phase":"PHASE4","title":"Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2014-02-04","conditions":"Type 2 Diabetes, Overweight","enrollment":48},{"nctId":"NCT03905707","phase":"PHASE3","title":"Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zealand Pharma","startDate":"2019-05-07","conditions":"Short Bowel Syndrome","enrollment":145},{"nctId":"NCT07360457","phase":"","title":"GLP1 Analogues and the Risk of Osteoarthritis","status":"NOT_YET_RECRUITING","sponsor":"Beni-Suef University","startDate":"2026-02-01","conditions":"Osteoarthritis","enrollment":390},{"nctId":"NCT03941236","phase":"PHASE3","title":"Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zealand Pharma","startDate":"2019-05-02","conditions":"Congenital Hyperinsulinism","enrollment":42},{"nctId":"NCT06904846","phase":"NA","title":"To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period","status":"ENROLLING_BY_INVITATION","sponsor":"Sinocare","startDate":"2025-04-23","conditions":"Diabetes Mellitus, Continuous Glucose Monitoring System","enrollment":70},{"nctId":"NCT02227849","phase":"PHASE4","title":"Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2014-08","conditions":"Type 2 Diabetes Mellitus","enrollment":71},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT07270497","phase":"","title":"The Effect of Pharmacotherapy With GLP-1 and GIP/GLP-1 Analogs on Changes in Qualitative and Quantitative Parameters of the Diet as Well as Metabolic and Behavioral Parameters in Patients With Excess Body Weight","status":"RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2025-08-15","conditions":"GLP-1, Nutrition","enrollment":100},{"nctId":"NCT07200622","phase":"PHASE2","title":"Oral Semaglutide in Patients With Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"Imperial College London","startDate":"2025-09-25","conditions":"Alzheimer Disease","enrollment":60},{"nctId":"NCT07042672","phase":"","title":"Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity","status":"RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2025-07-01","conditions":"Binge Eating Disorder Associated With Obesity, Binge Eating Disorder, Eating Disorder Binge","enrollment":80},{"nctId":"NCT05184322","phase":"PHASE1","title":"XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults","status":"COMPLETED","sponsor":"Sciwind Biosciences APAC CO Pty. Ltd.","startDate":"2022-04-12","conditions":"Obesity, Type 2 Diabetes Mellitus","enrollment":87},{"nctId":"NCT06621017","phase":"PHASE2","title":"Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects","status":"COMPLETED","sponsor":"Rose Pharma Inc","startDate":"2024-09-26","conditions":"Obesity; Overweight","enrollment":40},{"nctId":"NCT07111494","phase":"PHASE4","title":"Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-10-15","conditions":"Psoriatic Arthritis (PsA)","enrollment":22},{"nctId":"NCT03690206","phase":"PHASE3","title":"Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2018-10-04","conditions":"Short Bowel Syndrome","enrollment":106},{"nctId":"NCT05018286","phase":"PHASE3","title":"Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.","status":"ACTIVE_NOT_RECRUITING","sponsor":"VectivBio AG","startDate":"2021-07-13","conditions":"Short Bowel Syndrome","enrollment":158},{"nctId":"NCT07030621","phase":"PHASE3","title":"Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-07-01","conditions":"Acute Ischemic Stroke","enrollment":436},{"nctId":"NCT06101667","phase":"NA","title":"Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-10-15","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":224},{"nctId":"NCT05303857","phase":"PHASE4","title":"Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2022-03-03","conditions":"Diabetes Mellitus, Type 2","enrollment":107},{"nctId":"NCT06411210","phase":"PHASE2","title":"Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-07-16","conditions":"Diabetes type1, Obesity","enrollment":54},{"nctId":"NCT05725681","phase":"NA","title":"Satiety of High-Protein Ramen Noodles","status":"COMPLETED","sponsor":"Texas Tech University","startDate":"2023-06-01","conditions":"Appetitive Behavior","enrollment":30},{"nctId":"NCT04172441","phase":"PHASE2, PHASE3","title":"Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2020-06-19","conditions":"Congenital Hyperinsulinism","enrollment":12},{"nctId":"NCT06577584","phase":"","title":"Comparison of Diabetes Patients - Care Trajectory Versus Convention","status":"NOT_YET_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2025-02-01","conditions":"Type 2 Diabetes","enrollment":20000},{"nctId":"NCT06764056","phase":"NA","title":"Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)","status":"NOT_YET_RECRUITING","sponsor":"Institut universitaire de cardiologie et de pneumologie de Québec, University Laval","startDate":"2025-01","conditions":"Metabolic Associated Fatty Liver Disease, Metabolic Associated-dysfunction Steatohepatitis (MASH), Obesity","enrollment":120},{"nctId":"NCT04174755","phase":"NA","title":"Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV","status":"RECRUITING","sponsor":"University College Dublin","startDate":"2022-06-22","conditions":"Obesity, HIV-1-infection","enrollment":80},{"nctId":"NCT06682351","phase":"PHASE4","title":"Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2024-11","conditions":"Prediabetes / Type 2 Diabetes","enrollment":200},{"nctId":"NCT06527209","phase":"NA","title":"Effect of Coffee and Agave Inulin-based Beverage on Appetite in Adults With Obesity.","status":"ENROLLING_BY_INVITATION","sponsor":"University of Guadalajara","startDate":"2024-06-24","conditions":"Obesity","enrollment":30},{"nctId":"NCT06523101","phase":"PHASE1","title":"A Study of PJ009 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Chongqing Peg-Bio Biopharm Co., Ltd.","startDate":"2023-02-28","conditions":"Short Bowel Syndrome","enrollment":24},{"nctId":"NCT06240039","phase":"NA","title":"Direct Versus Indirect Effect of Amino Acids on Hepatokines","status":"NOT_YET_RECRUITING","sponsor":"University of Copenhagen","startDate":"2024-02","conditions":"Non-Alcoholic Fatty Liver Disease, Obesity","enrollment":30},{"nctId":"NCT06201819","phase":"PHASE4","title":"Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery","status":"COMPLETED","sponsor":"Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca","startDate":"2022-12-18","conditions":"Weight Loss, Bariatric Surgery Candidate, Obesity, Morbid","enrollment":37},{"nctId":"NCT05751720","phase":"PHASE1, PHASE2","title":"Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue","status":"UNKNOWN","sponsor":"Dr Adnan Agha","startDate":"2023-10-01","conditions":"Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Type 2 Diabetes","enrollment":30},{"nctId":"NCT05454709","phase":"PHASE2","title":"A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System","status":"WITHDRAWN","sponsor":"Inreda Diabetic B.V.","startDate":"2023-12-29","conditions":"Diabetes Mellitus, Type 1","enrollment":""},{"nctId":"NCT04186494","phase":"NA","title":"Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"St Vincent's University Hospital, Ireland","startDate":"2019-12-02","conditions":"Sleep Apnea, Obstructive","enrollment":30},{"nctId":"NCT03777176","phase":"PHASE3","title":"A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2019-02-07","conditions":"Congenital Hyperinsulinism","enrollment":32},{"nctId":"NCT06154486","phase":"","title":"Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-06-19","conditions":"Pneumonia, Aspiration, Anesthesia","enrollment":30},{"nctId":"NCT05111912","phase":"PHASE2","title":"Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity","status":"COMPLETED","sponsor":"Sciwind Biosciences APAC CO Pty. Ltd.","startDate":"2021-11-30","conditions":"Obesity","enrollment":206},{"nctId":"NCT05543850","phase":"NA","title":"Portable Artificial Pancreas Applied for Youth and Adolescents","status":"COMPLETED","sponsor":"Inreda Diabetic B.V.","startDate":"2022-10-28","conditions":"Diabetes Mellitus, Type 1","enrollment":20},{"nctId":"NCT05389813","phase":"PHASE2, PHASE3","title":"Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia","status":"UNKNOWN","sponsor":"An-Najah National University","startDate":"2021-08-15","conditions":"Anesthesia","enrollment":150},{"nctId":"NCT05095259","phase":"NA","title":"Metabolic Adaptation to High-frequent Hypoglycaemia in Type 1 Diabetes","status":"UNKNOWN","sponsor":"Nordsjaellands Hospital","startDate":"2019-12-16","conditions":"Type1diabetes","enrollment":60},{"nctId":"NCT05767255","phase":"PHASE3","title":"Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue","status":"UNKNOWN","sponsor":"Hospital Universitario San Ignacio","startDate":"2022-12-01","conditions":"Diabetes Mellitus, Type 2 Treated With Insulin","enrollment":66},{"nctId":"NCT02829502","phase":"PHASE2","title":"The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke","status":"UNKNOWN","sponsor":"Christina Kruuse","startDate":"2016-08","conditions":"Ischemic Stroke","enrollment":30},{"nctId":"NCT03895697","phase":"PHASE3","title":"A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2019-03-26","conditions":"Hypoglycemia, Diabetes Mellitus, Type 1","enrollment":92},{"nctId":"NCT02244164","phase":"NA","title":"Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2014-10","conditions":"Type 2 Diabetes, Incretinomimetics, Pancreas","enrollment":5},{"nctId":"NCT05569304","phase":"NA","title":"Endoscopic Sleeve Gastroplasty Versus GLP-1 Analogue for Class 1 and 2 Obesity Study","status":"UNKNOWN","sponsor":"Sengkang General Hospital","startDate":"2022-10-07","conditions":"Obesity","enrollment":66},{"nctId":"NCT04687514","phase":"PHASE2","title":"Effects of Glucagon-Like Peptide-1 Analogs on Sexuality","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-05-05","conditions":"Sexual Functioning","enrollment":26},{"nctId":"NCT05249881","phase":"EARLY_PHASE1","title":"\"Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan.\"","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2022-03-10","conditions":"Diabetes Mellitus, Type 2, Weight Change, Body","enrollment":300},{"nctId":"NCT04876027","phase":"PHASE4","title":"GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS)","status":"COMPLETED","sponsor":"Shanghai 10th People's Hospital","startDate":"2021-05-15","conditions":"Polycystic Ovary Syndrome","enrollment":68},{"nctId":"NCT02344186","phase":"PHASE4","title":"Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Temple University","startDate":"2014-05","conditions":"Type 2 Diabetes","enrollment":12},{"nctId":"NCT03422666","phase":"PHASE2, PHASE3","title":"Plasma Lipoprotein Response to Glucagon-like Peptide-2","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2018-09-21","conditions":"Hyperlipidemias","enrollment":10},{"nctId":"NCT03442972","phase":"PHASE2, PHASE3","title":"Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral Lipids","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2019-01-17","conditions":"Hyperlipidemias","enrollment":21},{"nctId":"NCT05360147","phase":"PHASE3","title":"Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Third Military Medical University","startDate":"2021-01-20","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT04969627","phase":"PHASE4","title":"Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.","status":"COMPLETED","sponsor":"Bing He","startDate":"2021-01-04","conditions":"Polycystic Ovary Syndrome","enrollment":60},{"nctId":"NCT01302327","phase":"NA","title":"GLP Analogs for Diabetes in Wolfram Syndrome Patients","status":"WITHDRAWN","sponsor":"Hadassah Medical Organization","startDate":"2011-03-01","conditions":"Diabetes Mellitus Associated With Genetic Syndrome, Wolfram Syndrome","enrollment":""},{"nctId":"NCT03415139","phase":"","title":"Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant","status":"UNKNOWN","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2019-03-12","conditions":"Diabetes Mellitus, Cancer","enrollment":120},{"nctId":"NCT02898506","phase":"PHASE2","title":"Incretin-based Therapy in Late Preclinical Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Oulu","startDate":"2016-03","conditions":"Type 1 Diabetes","enrollment":13},{"nctId":"NCT02611232","phase":"PHASE2","title":"Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults","status":"UNKNOWN","sponsor":"University of Oulu","startDate":"2015-12","conditions":"Type 1 Diabetes","enrollment":42},{"nctId":"NCT02908087","phase":"PHASE2","title":"Incretin-based Therapy in Early Diagnosed Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Oulu","startDate":"2016-03","conditions":"Type 1 Diabetes","enrollment":13},{"nctId":"NCT04389775","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants","status":"COMPLETED","sponsor":"Sciwind Biosciences APAC CO Pty. Ltd.","startDate":"2020-03-29","conditions":"Type 2 Diabetes Mellitus, Obesity, Nonalcoholic Steatohepatitis","enrollment":64},{"nctId":"NCT05029076","phase":"PHASE1","title":"Human Bioequivalence Test of Liraglutide Injection","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-05-21","conditions":"Type 2 Diabetes","enrollment":28},{"nctId":"NCT03430284","phase":"PHASE4","title":"Multifactorial Intervention on Diabetes (MIDiab Study)","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2018-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":6300},{"nctId":"NCT04146155","phase":"PHASE4","title":"Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-01","conditions":"Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus","enrollment":200},{"nctId":"NCT03667053","phase":"PHASE3","title":"Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2018-09-28","conditions":"Hypoglycemia","enrollment":42},{"nctId":"NCT03378635","phase":"PHASE3","title":"A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2017-12-07","conditions":"Hypoglycemia, Diabetes Mellitus, Type 1","enrollment":170},{"nctId":"NCT04626323","phase":"PHASE2","title":"Randomized Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease","status":"UNKNOWN","sponsor":"Hospital Alemão Oswaldo Cruz","startDate":"2021-05-25","conditions":"Diabetes Mellitus, Type 2, Kidney Disease, Chronic, Kidney Injury","enrollment":60},{"nctId":"NCT03688711","phase":"PHASE3","title":"Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2018-11-01","conditions":"Hypoglycemia, Diabetes Mellitus, Type 1","enrollment":45},{"nctId":"NCT03216226","phase":"PHASE3","title":"A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2017-06-28","conditions":"Hypoglycemia, Diabetes Mellitus, Type 1","enrollment":112},{"nctId":"NCT03860688","phase":"PHASE2, PHASE3","title":"Effects of Oral Glucose and Teduglutide on Plasma Lipoproteins","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2019-05-01","conditions":"Hyperlipidemias","enrollment":15},{"nctId":"NCT03157063","phase":"","title":"Pilot Data Collection for Activity, Adiposity, and Appetite in Adolescents","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2017-01-01","conditions":"Physical Activity, Sedentary Lifestyle, Metabolism","enrollment":64},{"nctId":"NCT02971228","phase":"PHASE2","title":"Feasibility Trial Testing the Bionic Pancreas With ZP4207","status":"COMPLETED","sponsor":"Zealand Pharma","startDate":"2016-11","conditions":"Diabetes Mellitus, Type 1","enrollment":13},{"nctId":"NCT03819790","phase":"PHASE4","title":"The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians","status":"COMPLETED","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2018-10-02","conditions":"Diabetes Mellitus, Type 2","enrollment":119},{"nctId":"NCT03859323","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending, Subcutaneous, Single and Multiple Doses of SHP681 (Glucagon-like Peptide-2 [GLP-2] Analog-Fc Fusion) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Shire","startDate":"2019-03-26","conditions":"Healthy Volunteers","enrollment":104},{"nctId":"NCT02692040","phase":"PHASE1","title":"Study of the Gut Hormone Analogue G3215 in Adult Subjects","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2015-01","conditions":"Diabetes Mellitus, Obesity","enrollment":90},{"nctId":"NCT04379856","phase":"PHASE1, PHASE2","title":"Proof of Concept Study in Patients With Short Bowel Syndrome","status":"UNKNOWN","sponsor":"9 Meters Biopharma, Inc.","startDate":"2020-06-23","conditions":"Short Bowel Syndrome","enrollment":12},{"nctId":"NCT02537834","phase":"PHASE4","title":"Tofogliflozin GLP-1 Analogue Combination Trial","status":"COMPLETED","sponsor":"Kowa Company, Ltd.","startDate":"2015-08","conditions":"Type 2 Diabetes Mellitus","enrollment":65},{"nctId":"NCT01795248","phase":"PHASE4","title":"The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes","status":"COMPLETED","sponsor":"Tina Vilsboll","startDate":"2012-07","conditions":"Gestational Diabetes Mellitus","enrollment":105},{"nctId":"NCT04122716","phase":"PHASE4","title":"Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet","status":"UNKNOWN","sponsor":"Signe Torekov","startDate":"2016-09","conditions":"Obesity","enrollment":215},{"nctId":"NCT04196231","phase":"PHASE4","title":"Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2019-11-27","conditions":"Type 2 Diabetes","enrollment":258},{"nctId":"NCT02920190","phase":"PHASE4","title":"Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2020-09-01","conditions":"Monoclonal Gammopathies, Overweight, Obesity","enrollment":""},{"nctId":"NCT02043054","phase":"PHASE3","title":"Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":90},{"nctId":"NCT01856790","phase":"EARLY_PHASE1","title":"Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes","status":"COMPLETED","sponsor":"Jennifer Sherr","startDate":"2013-02","conditions":"Type 1 Diabetes","enrollment":15},{"nctId":"NCT02694575","phase":"","title":"The Impact of Glucose Lowering Therapies on Circulating Endothelial Progenitor Cells and Its Mobilising Factor Stromal Derived Factor-1α in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2015-03-01","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":241},{"nctId":"NCT03507621","phase":"","title":"Sevoflurane Versus Propofol; Neuro Endocrine Response in Patients of Oociyt Pick up","status":"COMPLETED","sponsor":"Yavuz Orak","startDate":"2018-04-30","conditions":"Anesthesia, Infertility, Pain, Postoperative","enrollment":60},{"nctId":"NCT01865760","phase":"NA","title":"Etiology, Assessment and Treatment of Post-gastric Bypass Severe Hypoglycemia","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2013-06","conditions":"Obesity, Hypoglycemia, Surgery","enrollment":33},{"nctId":"NCT04105608","phase":"NA","title":"GLP-1 and Oxyntomodulin Release in Relation to Diet in Type 2 Diabetes Patients.","status":"COMPLETED","sponsor":"Antonio Di Mauro","startDate":"2017-11-01","conditions":"Type-2 Diabetes","enrollment":12},{"nctId":"NCT01234649","phase":"PHASE3","title":"Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)","status":"COMPLETED","sponsor":"Woman's","startDate":"2011-08-11","conditions":"Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome","enrollment":153},{"nctId":"NCT02846857","phase":"PHASE2","title":"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 15 Weeks in Adolescents and Adults With Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"","conditions":"Type 1 Diabetes","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":421,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["incretin-based drugs","exenatide","liraglutide"],"phase":"phase_2","status":"active","brandName":"GLP-1 analogs","genericName":"GLP-1 analogs","companyName":"Canadian Network for Observational Drug Effect Studies, CNODES","companyId":"canadian-network-for-observational-drug-effect-studies-cnodes","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GLP-1 analogs mimic the action of the hormone glucagon-like peptide-1 to regulate blood sugar levels. Used for Type 2 diabetes, Weight management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}